Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 788

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 788
---
 dividends from the date of issuance to December 31, 2024 were not significant. Common Shares As of December 31, 2024, the Company had 3,159,535registered and issued Company Common Shares. On December 4, 2024, the Company, entered into a securities purchase agreement, or the December SPA, with a certain accredited investor and agreed to issue and sell to the investor, in a private placement offering, or the SPA Offering, up to 322,580Company Common Shares, at a purchase price of $ 3.10per Company Common Share for aggregate gross proceeds of up to $ 1million, subject to shareholder approval, or the Shareholder Approval. The offering was structured in two tranches, with the first tranche of $ 500,000closing following shareholder approval. The Company has also agreed that (i) on or before January 15, 2025, or sooner contemporaneously with the Shareholder Approval, the Company will take all steps necessary to obtain all approvals, including shareholder approval, necessary to reduce the par value of the Company Common Shares to the minimum permissible par value which shall not be greater than CHF 0.03per Company Common Share; (ii) on or before January 9, 2025, the Company will authorize and reserve sufficient Company Common Shares to satisfy the anti -dilutionand ratchet rights of the Purchaser under the prior securities purchase agreement dated October 9, 2024, or the October SPA, after giving effect to the conversion price reduction of the preferred shares as a result of the Dilutive Issuances (as defined in the October SPA) caused Annex F-22 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS by the Company entering into Securities Purchase Agreement; and (iii) in addition to the Company’s obligations pursuant to the October SPA. The second tranche of $ 500,000may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the Common Shares trading for at least ten consecutive trading days above the purchase price of $ 3.10, which corresponds to an approximate 15% premium. As of December 31, 2024, the conditions for closing have not yet occurred. See Note 13 for further details. In addition, the Company has agreed to register the Company Common Shares subject to the terms of the previously